Infantile hemangioma (IH) is a benign tumor that is formed by aberrant angiogenesis and that undergoes spontaneous regression over time. Propranolol, the first-line therapy for IH, inhibits angiogenesis by downregulating activation of the vascular endothelial growth factor (VEGF) pathway, which is hyperactivated in IH. However, this treatment is reportedly ineffective for 10% of tumors, and 19% of patients relapse after propranolol treatment. Both pro-angiogenic and anti-angiogenic factors regulate angiogenesis, and pigment epithelium-derived factor (PEDF) is the most effective endogenous anti-angiogenic factor. PEDF/VEGF ratio controls many angiogenic processes, but its role in IH and the relationship between this ratio and propranolol remain unknown. Results of the present study showed that the PEDF/ VEGF ratio increased during the involuting phase of IH compared with the proliferating phase. Similarly, in hemangioma-derived endothelial cells (HemEC), which were isolated with magnetic beads, increasing the PEDF/VEGF ratio inhibited proliferation, migration, and tube formation and promoted apoptosis. Mechanistically, the VEGF receptors (VEGFR1 and VEGFR2) and PEDF receptor (laminin receptor, LR) were highly expressed in both IH tissues and HemEC, and PEDF inhibited HemEC function by binding to LR. Interestingly, we found that propranolol increased the PEDF/VEGF ratio but did so by lowering VEGF expression rather than by upregulating PEDF as expected. Furthermore, the combination of PEDF and propranolol had a more suppressive effect on HemEC. Consequently, our results suggested that the PEDF/VEGF ratio played a pivotal role in the spontaneous regression of IH and that the combination of PEDF and propranolol might be a promising treatment strategy for propranolol-resistant IH.
| INTRODUCTION
Infantile hemangioma is one of the most common vascular tumors and occurs in approximately 5%-10% of infants. 1, 2 Although IH is a benign tumor, IH can severely affect the appearance and psychology of a child because 60% of IH occur around the head and neck. Moreover, serious cases can become life-threatening when the IH affect specific regions containing functional organs. 3, 4 This unique tumor comprises an increased number of unique EC that lead to rapid angiogenesis. 5 IH usually forms within the first week after birth and grows rapidly during the first 3-6 months, known as the proliferating phase of IH. 6 Subsequently, spontaneous regression occurs from 12 months to 5 years of age and beyond. 7, 8 Currently, the specific pathogenesis and molecular mechanisms underlying this spontaneous involution are largely unknown. The VEGF pathway is a well-known regulatory mechanism. 9 VEGF and VEGF receptors are overactivated during the proliferating phase of IH. As its name implies, VEGF stimulates EC proliferation, mitogenesis, and migration and subsequently initiates rapid angiogenesis. 10, 11 However, both physiological and pathological angiogenesis is regulated by a balance of pro-angiogenic and anti-angiogenic factors.
The roles of anti-angiogenic factors and their mechanisms in IH progression have received little attention.
PEDF is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. In addition, PEDF is the most active endogenous anti-angiogenic factor and can directly target EC to inhibit EC proliferation and promote cell apoptosis. 12, 13 Recent studies have found that PEDF is highly expressed in the involuting phases of IH. 14, 15 Previous investigations, including ours, have confirmed that the balance between PEDF and VEGF plays a crucial role in the processes of vascular development and angiogenesis. 13, [16] [17] [18] [19] [20] [21] Nevertheless, whether and how the PEDF/ VEGF ratio plays a role in IH is unclear. Herein, we found that the PEDF/VEGF ratio was increased during the involuting phase of IH compared to during the control proliferating phase of IH and compared to VM. To investigate the role of the PEDF/VEGF ratio in vitro, we separated HemEC with magnetic beads. Accordingly, the PEDF/VEGF ratio clearly inhibited HemEC proliferation, migration, and tube formation and induced HemEC apoptosis in a specific receptor-dependent way.
Although IH can disappear without treatment, IH regression takes many years, and a significant proportion of lesions require some form of therapy as a result of their specific locations. In 2008,
Leaute-Labreze serendipitously found that propranolol, a b-AR antagonist, could effectively inhibit IH growth and, thereafter, propranolol has been the first-line treatment for IH. 22 Nevertheless, the use of propranolol is not without problems. Approximately 10% of tumors do not respond, 23 whereas 19% of patients experience relapsed growth within the first year of life. 24, 25 Indeed, current researchers are mostly focusing on the effects of propranolol on the expression of pro-angiogenic factors, especially VEGF. Multiple studies have shown that VEGF expression is downregulated after giving propranolol. [26] [27] [28] However, the possible impact of propranolol on anti-angiogenic factors and the balance in the PEDF/VEGF ratio remain unknown to date. Surprisingly, we found that propranolol increased the PEDF/VEGF ratio primarily by reducing VEGF expression but also by reducing PEDF expression in vivo and in vitro.
However, when we artificially modified the PEDF/VEGF ratio by combining PEDF with propranolol, we observed a better inhibitory effect in HemEC. This study highlights the potential utility of natural medicine in the treatment of propranolol-resistant IH.
| MATERIALS AND METHODS

| Immunohistochemistry
To investigate whether the PEDF/VEGF ratio contributed to IH pro- veins according to a protocol described previously. 31 These cells were cultured in EGM-2 with 100 U/mL streptomycin (Gibco) in an atmosphere of 5% CO 2 at 37°C.
| Cell viability assay
Recombinant PEDF was expressed and purified as described previously. 12 Recombinant human VEGF165 protein (VEGF) was pur- | 1983 paraformaldehyde and stained with 0.1% crystal violet, and images were obtained using a digital camera coupled with a microscope.
Last, relative migration was quantified using ImageJ software.
| Tube formation assay
Tube formation abilities of HemEC and HUVEC were assessed in vitro. Matrigel (BD Biosciences, San Jose, CA, USA) was thawed at 4°C overnight, and 100 lL Matrigel was evenly added to each well of a precooled 24-well plate. The plate was then incubated at 37°C for 30 minutes. Cells (2 9 10 5 ) in 1-mL suspensions were seeded to the top of the matrix in the 24-well plate and incubated at 37°C for 12 hours. The cells were subjected to different treatments, as described above. Then, the capillary-like structures were photographed under a light microscope using an Inverted Fluorescence Microscope (1 9 71; Olympus, Tokyo, Japan), and the tubes were scanned and quantified using ImageJ software.
| Immunoblotting (western blotting)
Cells were harvested and lysed for total protein extraction using SDS sample buffer, followed by boiling for 30 minutes. Protein concentrations were measured using a BCA protein assay kit (KeyGEN BioTECH, Nanjing, China) according to the manufacturer's protocol.
SDS-PAGE was carried out to resolve each sample (25 lg), and 8%-15% gradient gels were used. The proteins were transferred to 4.5- and b-actin (1:5000). Densitometry was carried out using ImageJ software.
| Co-immunoprecipitation
We carried out a co-IP analysis to determine whether PEDF could bind to LR in vitro. We first washed 1 
| Enzyme-linked immunosorbent assay
To measure protein expression in the serum before and after propranolol treatment, we collected paired peripheral blood serum samples from the 20 IH patients and stored these samples in liquid nitrogen until use. Informed consent was provided by all study participants.
The participants were clinically diagnosed with IH at the Guangzhou Women and Children's Hospital between 2015 and 2016. Finally, serum PEDF and VEGF levels were measured using human PEDF (R&D Systems) and VEGF-A (R&D Systems) ELISA kits, respectively, according to the manufacturer's protocols.
| Quantitative real-time PCR (qPCR)
We carried out a qPCR assay to evaluate PEDF and VEGF expression at the mRNA level. Total RNA was extracted from HemEC by Trizol Reagent (Invitrogen). Total RNA (500 ng) was used for reverse transcription and qPCR. Target mRNA was determined using the capillary-based Light Cycler 2.0 Systems (Roche Diagnostics Corporation, Indianapolis, IN, USA). b-Actin was used as an internal control. cDNA was amplified with special primers for PEDF (forward,
| Statistical analyses
Standard t tests were used to compare 2 groups; 1-way analysis of variance was used to compare more than 2 groups. Paired t tests were used to compare paired samples. Statistical analysis was carried out using SPSS 13.0 software. P < .05 indicated a statistically significant difference.
3 | RESULTS
| PEDF/VEGF ratio is increased during the involuting phase of IH
The proliferating phase of IH is characterized by immature vessels that are formed as a result of densely packed tumor cells. Features of the involuting phase include blurred boundaries between EC, mature and expanded blood vessels and the gradual apoptosis of EC. 32 These features are obvious by HE staining ( Figure 1A , top row). VM is a subtype of vascular malformation that affects the venous vasculature and is usually congenital and found at birth.
Because the EC of VM arise from a non-proliferative quiescent state in contrast to hemangioma EC, 33 we used VM tissues as a relative control. Many reports have confirmed that pro-angiogenic factors, F I G U R E 1 Pigment epithelium-derived factor/vascular endothelial growth factor (PEDF/VEGF) ratio is increased during the involuting phase of infant hemangioma (IH). A, Paraffin tissue sections representative of different phases of IH and venous malformation (VM) were subjected to immunohistochemistry with the specific anti-PEDF (middle row) and anti-VEGF-A (bottom row) antibodies. H&E staining indicates histopathological structures (top row); magnification: 4009; scale bar: 50 lm. B, Histogram indicates average immunohistochemistry scores for the different groups: VM (n = 5), proliferating phase of IH (n = 12), and involuting phase of IH (n = 10). Columns indicate mean AE SEM, *P < .05, **P < .01. C, Immunofluorescence staining of endothelial cell (EC) marker CD31 (green) and pericyte marker a-smooth muscle actin (a-SMA) (red) for the different phases of IH. Nuclei were stained with DAPI (blue). White arrows indicate the blood vessels that are expanding and maturing; scale bar: 100 lm. Histogram represents the microvessel density of each field, and the columns indicate the mean AE SEM, ***P < .001 especially VEGF, are excessively expressed to facilitate the proliferation of IH in an autocrine method. 34 We found that VEGF expression was increased in all IH specimens compared to VM specimens ( Figure 1A , bottom row). In contrast, PEDF staining was strongest during the involuting phase of IH ( Figure 1A , middle row) and higher than in the proliferating phase ( Figure 1B) . We calculated the relative ratio of PEDF/VEGF and found that the ratio was decreased during the proliferating phase and increased during the involuting phase ( Figure 1B) . These results indicated that the PEDF/VEGF ratio may play a crucial role in the spontaneous regression of IH. In addition, by immunofluorescence staining of the endothelium and of pericyte markers, we found that the microvascular density was reduced and that the vessel structures were expanded and matured during the involuting phase of IH ( Figure 1C ). These features of EC regression occurred simultaneously to the increase in the PEDF/VEGF ratio, thus indicating that upregulation of the PEDF/VEGF ratio may influence EC function to induce IH regression.
| Upregulation of the PEDF/VEGF ratio inhibits HemEC viability and induces apoptosis
Infantile hemangioma comprises unique EC but lacks corresponding cell lines for investigation. 5 Thus, we digested cells from 3 IH patients (Table S1) HUVEC were used as a positive control for EC. As observed with HUVEC, HemEC highly expressed EC characteristics; however, nonHemEC showed high expression levels of a pericyte/fibroblast marker (a-SMA) ( Figure 2B ; Figure S1 ). We set the effective VEGF concentration to 50 ng/mL based on preliminary experiments and increased the PEDF/VEGF ratio by gradually increasing the PEDF concentration. PEDF-treated groups of HemEC and HUVEC showed dose-dependent inhibition in cell viability, and HemEC were more sensitive than HUVEC ( Figure 2C ). Moreover, increasing the PEDF/ VEGF ratio induced HemEC apoptosis ( Figure 2D ,E). We treated HemEC with PEDF alone and found that the pro-apoptotic effect was mainly achieved by PEDF ( Figure 2F ,G) and resulted in the cleavage of apoptotic protein caspase3 ( Figure 2H ). These results suggested that increasing the PEDF/VEGF ratio induced HemEC apoptosis to promote IH regression.
| Increasing the PEDF/VEGF ratio inhibits HemEC migration and tube formation
Given the importance of VEGF and PEDF in endothelial migration, 35 we carried out Boyden cell migration assays to determine whether the PEDF/VEGF ratio affected HemEC migration. The results showed that PEDF reduced HemEC migration in a concentrationdependent method compared to VEGF alone ( Figure 3A,B) . This and triggers downstream signals to promote angiogenesis. 36, 37 Multiple studies have confirmed that the hyperactivation of VEGF-VEGFR-2 pathways in IH induces downstream signaling to promote IH angiogenesis. 10, 34 Consistent with these reports, we found that the expression levels of both VEGFR1 and VEGFR2 were significantly higher in IH tissues than in VM tissues ( Figure 4 ). PEDF is a well-known secreted protein that regulates EC functions, depending on specific receptors in an autocrine or paracrine method. 35 In recent years, several PEDF receptors (ATGL/LR/LRP6) have been reported, where LR and LRP6 mediate the anti-angiogenic effects of PEDF in EC and cancer cells. 38, 39 However, until now, the expression of PEDF receptor in IH tissues has not been addressed. We found that LR staining was obviously stronger in both proliferating and involuting phases of IH than in VM (Figure 4 ). Nevertheless, LRP6
was nearly undetectable in IH tissue sections after staining with a specific antibody ( Figure 4A ). Moreover, in serial sections that were examined by immunofluorescence, we found that the receptors for VEGF and PEDF were mainly located in EC and merged with CD31 staining ( Figure 5 , denoted by white arrows; the red arrows indicate that some non-HemEC also express LR and VEGFR1). Here, we were primarily concerned with HemEC and hypothesized that VEGF exerted its pro-angiogenic effects through its receptors (VEGFR1 and VEGFR2) in the EC of IH as previously reported, whereas PEDF carried out its anti-angiogenic actions primarily through LR.
| PEDF inhibits HemEC functions by binding to LR
To further test the above hypothesis in vitro, we examined the expression levels of the above-mentioned receptors in HemEC.
Expression levels of VEGFR1, VEGFR2, and LR were obviously increased in HemEC compared to HUVEC ( Figure 6A 
| PEDF and propranolol combination achieves greater suppression of HemEC
Propranolol has recently emerged as the first-line drug for IH and causes tumor regression. 22, 27 Propranolol induces vasoconstriction through its effect on nitric oxide, blocks angiogenesis through its effect on VEGF and induces apoptosis. We examined the expression levels of 3 b-AR. As observed in previous studies, 40 all 3 receptors were overexpressed in IH ( Figure S4 ), and the majority of these receptors were merged with CD31 ( Figure S5 ). Many published articles have indicated that propranolol inhibits VEGF expression. 26, 27, 41 However, the mechanism through which propranolol affects the most active anti-angiogenesis factor, PEDF, has not been explored.
Here, we collected paired blood sera from 20 IH patients before and after oral propranolol treatment and measured the expression levels of VEGF and PEDF by ELISA. Expression levels of serum VEGF were significantly reduced after 1 month of oral propranolol treatment ( Figure 7A) . Surprisingly, the PEDF levels were also lower, and this decrease was statistically significant ( Figure 7B ) and consequently resulted in a slightly higher relative PEDF/VEGF ratio ( Figure 7C ).
These results indicated that propranolol caused regression mainly through its effect on VEGF rather than on PEDF. We verified these results in cell-based experiments and found that HemEC proliferation was inhibited by propranolol after 24 hours ( Figure 7D ). Similarly, propranolol downregulated the expression of PEDF in a dose-dependent method at the mRNA ( Figure 7E ) and protein levels ( Figure 7F ), in contrast to the presumed notion that propranolol upregulated PEDF. The relative increase in the PEDF/VEGF ratio was mainly as a result of a more pronounced decrease in VEGF expression in several of the propranolol treatment groups. This may be a possible explanation for the relapse after propranolol dosage in 19% of patients.
Moreover, HemEC proliferation was better inhibited by the combination of PEDF and propranolol ( Figure 7G ). Therefore, these data provide a promising new therapeutic strategy for propranolol-resistant IH.
| DISCUSSION
In the present study, we found that the development of IH was regulated by the PEDF/VEGF ratio in the abnormal endothelium through specific receptors. This study has extended our understanding of the pathogenesis of IH and indicates that spontaneous regression is regulated by a balance between pro-angiogenic factors and anti-angiogenic factors. Multiple investigators have found that to be regulated by PEDF through its specific receptor, LR. Interestingly, we found that propranolol increased the PEDF/VEGF ratio mainly by decreasing VEGF expression while also lowering PEDF levels in vivo and in vitro. In this way, the artificial modification of the PEDF/VEGF ratio with the PEDF and propranolol combination can achieve a better effect toward HemEC inhibition.
Pigment epithelium-derived factor is a 50-kDa secreted glycoprotein that belongs to the non-inhibitory serpin group and has been described as a potent anti-angiogenic factor. 13, 42 Until now, PEDF has been regarded as a suppressor of ischemia-induced retinal neovascularization, VEGF-induced migration and growth, 43 and EC migration and proliferation. 13 Consistent with studies published in 2014
and 2017, 14, 15 we found that the increased PEDF/VEGF ratio during the involuting phase of IH may be caused by both a decrease in VEGF and an increase in PEDF and that this increase is accompanied by a lower microvascular density and expanded blood vessel structures ( Figure 1 ). Furthermore, our results indicated that an increased PEDF/VEGF ratio could impact IH progression by inhibiting HemEC processes, including proliferation, apoptosis, migration, and tube formation (Figures 2 and 3) . However, the molecules that shift the balance toward PEDF and away from VEGF in the spontaneous regression of IH are still unknown. Reports have shown that hypoxia, or low oxygen conditions, led to VEGF upregulation and PEDF downregulation. 16 Another mechanism might involve adipose cells.
PEDF is widely expressed in plasma and most organs, especially in the liver and adipose tissue. our results showed that the expression levels of VEGF and VEGFR were upregulated in the EC of hemangiomas compared with the relatively quiescent EC. In contrast to previous studies, we found a major anti-angiogenic pathway in IH. We first showed that LR was highly expressed in IH and could be merged with EC (Figures 4 and   5 ) and found that PEDF bound to LR, and selectively inhibited HemEC through LR ( Figure 6 ). A previous study reported that PEDF promoted simulated-EC apoptosis through activating JNK/NFAT signaling, 45 and other researchers showed that PEDF could induce phosphorylation of JNK through LR and promote EC apoptosis by caspase3 activation. 39 Therefore, we examined the levels of p-JNK and total JNK in HemEC after increasing the PEDF/VEGF ratio. We also found that PEDF promoted HemEC apoptosis by increasing the phosphorylation of JNK and cleavage of caspase3 ( Figure S6A ), which was consistent with previous reports. 39 VEGF can induce the PI3K/AKT/eNOS pathway to promote angiogenesis. 46 Additionally, PEDF can inhibit VEGF-induced migration and tube formation by blocking VEGF-induced PI3K/Akt phosphorylation in bovine retinal EC. 47 As shown in Figure S6B ,C, we found that the level of p-AKT was higher in the proliferation phase of IH than in the involuting phase and, in vitro, PEDF could also inhibit the VEGF-induced AKT/ eNOS pathway transduction in HemEC. This indicated that PEDF and VEGF have important regulatory effects on the signaling pathways in HemEC through their respective receptors.
Although we have determined the functions of VEGF and PEDF on HemEC, the effects on other cells need further exploration. During our analysis, we noticed that the receptors for VEGF and PEDF were also located on some non-HemEC and are denoted by red arrows in Figure 5 . Propranolol, a non-selective b-AR blocker, has been the first-line treatment for IH since 2008. 22 We and others have found that b-AR are overexpressed in IH. 40 Indeed, in studies of the pharmacological mechanism, multiple researchers have focused on the effects of propranolol on pro-angiogenic factors. The data indicated that VEGF levels were reduced by propranolol in a dose-dependent method in vitro, 53 and significantly decreased expression levels of serum VEGF have been shown in IH after 1 and 2 months of propranolol treatment. 26, 54 Our data showed the same expression trend. However, we are the first to indicate the impact of propranolol on antiangiogenic factors. Surprisingly, serum PEDF level was also lowered by oral propranolol treatment, and the same results were observed in cell-based experiments ( Figure 7 ). These results may explain the rebound growth after the cessation of propranolol that is observed in 19% of cases during the first year after birth. 25 However, propranolol increased the PEDF/VEGF ratio mainly by decreasing VEGF expression. Whether the reduced expression of PEDF after propranolol treatment is related to propranolol resistance remains unknown. Hopefully, more studies will be conducted to address this problem. Our report presents a promising solution involving the application of a PEDF and propranolol combination treatment where the artificial increase in the PEDF/VEGF ratio is more remarkable and the inhibition of HemEC proliferation is more significant than those of propranolol alone. This study presents several options for a 
